Lutz Jacobasch
Overview
Explore the profile of Lutz Jacobasch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tintelnot J, Paschold L, Goekkurt E, Schultheiss C, Matschl U, Santos Cruz M, et al.
Cancer Immunol Res
. 2024 Nov;
13(2):200-209.
PMID: 39527097
Anti-PD-1, trastuzumab, and chemotherapy are used in the treatment of patients with advanced HER2-positive esophagogastric adenocarcinoma, but long-term survival remains limited. In this study, we report extended follow-up data from...
2.
Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, Furstenau M, et al.
J Clin Oncol
. 2024 Aug;
43(4):381-391.
PMID: 39213466
Purpose: Surrogate end points are commonly used to estimate treatment efficacy in clinical studies of chronic lymphocytic leukemia (CLL). This patient- and trial-level analysis describes the correlation between progression-free survival...
3.
Vogel A, Saborowski A, Wenzel P, Wege H, Folprecht G, Kretzschmar A, et al.
Lancet Gastroenterol Hepatol
. 2024 Jun;
9(8):734-744.
PMID: 38870977
Background: There is an unmet need for effective therapies in pretreated advanced biliary tract cancer. We aimed to evaluate the efficacy of nanoliposomal irinotecan and fluorouracil plus leucovorin compared with...
4.
Ettrich T, Modest D, Sinn M, Striefler J, Opitz B, Goetze T, et al.
J Clin Oncol
. 2024 Jun;
42(26):3094-3104.
PMID: 38843469
Purpose: First-line therapy options in advanced cholangiocarcinoma (CCA) are based on the ABC-02 trial regimen (gemcitabine/cisplatin [G/C]). The NIFE trial examined nanoliposomal irinotecan/fluorouracil/leucovorin (nal-IRI/FU/LV) as alternative first-line therapy in advanced...
5.
Koschmieder S, Isfort S, Schulte C, Jacobasch L, Geer T, Reiser M, et al.
Ann Hematol
. 2023 Oct;
102(12):3383-3399.
PMID: 37792065
Ruxolitinib (RUX) is a Janus kinase 1/2 inhibitor (JAKi) approved in the EU for treating disease‑related splenomegaly or symptoms in adults patients with myelofibrosis (MF). This is an interim analysis...
6.
Modest D, Karthaus M, Kasper S, Moosmann N, Keitel V, Kiani A, et al.
Eur J Cancer
. 2022 Aug;
173:297-306.
PMID: 35970102
Purpose: This trial investigates the addition of panitumumab to chemotherapy with fluorouracil/folinic acid and oxaliplatin (FOLFOX) in a 2:1 randomised, controlled, open-label, phase II trial in RAS wild-type colorectal cancer...
7.
Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes S, Simnica D, et al.
JAMA Oncol
. 2022 Jun;
8(8):1150-1158.
PMID: 35737383
Importance: In metastatic esophagogastric adenocarcinoma (EGA), the addition of programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in selected patient populations. Objective: To investigate the efficacy of...
8.
Crodel C, Jentsch-Ullrich K, Reiser M, Jacobasch L, Sauer A, Tesch H, et al.
J Cancer Res Clin Oncol
. 2021 Nov;
148(10):2693-2705.
PMID: 34807311
Purpose: Patients with polycythemia vera (PV) show an elevated incidence of thromboembolic complications and decreased survival when compared to age-matched healthy individuals. Hypercellularity as indicated by elevated hematocrit, pathophysiological changes...
9.
Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer G, Fietkau R, et al.
JAMA Oncol
. 2021 Nov;
8(1):e215445.
PMID: 34792531
Importance: Total neoadjuvant therapy has been increasingly adopted for multimodal rectal cancer treatment. The optimal sequence of chemoradiotherapy (CRT) and chemotherapy needs to be established. Objective: To report the long-term...
10.
Furstenau M, Giza A, Stumpf T, Robrecht S, Maurer C, Linde H, et al.
Am J Hematol
. 2021 Sep;
96(12):E457-E460.
PMID: 34591989
No abstract available.